Docoh
Loading...

PVCT Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. It engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

Company profile

Ticker
PVCT
Exchange
CEO
Bruce Horowitz
Employees
Incorporated
Location
Fiscal year end
Former names
PROVECTUS PHARMACEUTICAL INC, PROVECTUS PHARMACEUTICALS INC, SPM GROUP INC, ZAMAGE DIGITAL IMAGING INC
SEC CIK
IRS number
900031917

PVCT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 May 21
3 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 349.77K 349.77K 349.77K 349.77K 349.77K 349.77K
Cash burn (monthly) (positive/no burn) (positive/no burn) 393.56K 391.33K 371.16K 373.58K
Cash used (since last report) n/a n/a 1.63M 1.62M 1.53M 1.54M
Cash remaining n/a n/a -1.28M -1.27M -1.18M -1.19M
Runway (months of cash) n/a n/a -3.2 -3.2 -3.2 -3.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
20 Jun 21 Eric PHD Wachter Series D-1 Convertible Preferred Stock Common Stock Option exercise Aquire M No No 0 1,393,276 0 1,393,276
20 Jun 21 Bruce Horowitz Series D-1 Convertible Preferred Stock Common Stock Option exercise Aquire M No No 0 38,473 0 38,473
20 Jun 21 Pershing Edward Series D-1 Convertible Preferred Stock Common Stock Option exercise Aquire M No No 0 478,926 0 478,926
20 Jun 21 Webster Bailey Series D-1 Convertible Preferred Stock Common Stock Option exercise Aquire M No No 0 41,323 0 41,323
20 Jun 21 Heather Raines Series D-1 Convertible Preferred Stock Common Stock Option exercise Aquire M No No 0 20,289 0 20,289

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
  • Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on an entire, wholly owned, family of small molecules called HXs. The Company’s lead HX molecule is proprietary cGMP RBD. IL PV-10, a cancer immunotherapy and injectable formulation of cGMP RBD, can induce immunogenic cell death (“ICD”), and is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., HCC, mCRC, mNET, mUM), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma). Topically-administered PH-10, an immune-modulatory agent and formulation of cGMP RBD, is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). New formulations of and routes of administration for cGMP RBD are being investigated for hematology (e.g., acute myeloid leukemia, acute monocytic leukemia), virology (e.g., SARS-CoV-2), oncology (e.g., high-risk and refractory adult solid tumor cancers), microbiology (e.g., MDR bacteria), and ophthalmology (e.g., infectious keratitis).
  • The SARS-CoV-2 pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds and may also impact the volatility of our stock price and trading in our stock. Moreover, the pandemic has also significantly impacted economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the SARS-CoV-2 pandemic will be on our business. It has the potential to adversely affect our business, financial condition, results of operations, and prospects. We have taken several temporary precautionary measures intended to help ensure the well-being of our employees and contractors and to minimize disruption to our business. We considered the impact of SARS-CoV-2 pandemic on our business and operational assumptions and estimates, and determined there were no material adverse impacts on our results of operations and financial position at March 31, 2021.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: accelerated, Additionally, AFCO, aim, arising, automatically, aware, balance, bear, candidate, clarifying, curative, customary, discretion, equal, event, hold, individually, IP, lien, maximizing, monotherapy, Notwithstanding, ODD, ordinary, pari, passu, payment, penalty, pending, percent, Premium, priority, recruitment, refractory, relapsed, removing, resolved, simplify, Simplifying, subordinate, testicular, threatened, vi, wholly
Removed: addressed, affirmed, alter, alternative, amend, amendment, American, appeal, April, arbitrating, arbitration, arbitrator, Audit, autolytic, average, award, borrower, carryback, Chancery, Chief, claim, clarification, closure, collection, Committee, conducted, confirm, confirming, contractual, County, court, credit, Culpepper, Davidson, decreased, deduction, default, deferment, deferral, depository, Derivative, determining, Disaster, disbursement, dispute, disputed, economic, EIDL, eligible, employer, employment, enactment, enforcing, entitled, established, evaluating, excluding, favor, February, final, forgivable, improper, initial, Injury, investigation, issue, judgment, Kleba, Lawsuit, legislation, lending, long, longer, measuring, mediation, monthly, motion, Mutual, negotiated, notice, November, October, order, owed, participated, Paycheck, permission, Peter, petition, portion, PPP, President, proportionate, Protection, provision, qualified, qualifying, reached, recognized, recordation, refundable, regaining, relate, remaining, rent, repaid, reserve, resolution, Restated, September, Settlement, side, social, Stipulated, submitted, substantially, Supreme, tax, technical, terminate, terminated, termination, Trump, unanimously, unforgiven, upheld, varying, voted